In-house & bespoke training:
Biopharma

Biopharmaceuticals, known colloquially as biopharma, are the point at which biotechnology and pharmaceutical manufacturing meet. Biopharma is the application of living organisms or extractions, by-products or components of living organisms, to prevent, relieve, or treat diseases.

Management Forum’s biopharma training courses provide an extensive series of training opportunities covering a variety of topics, including the development of biopharmaceuticals, clinical trial requirements, manufacture, regulations and applicable standards. Our courses also provide insight into the use of emerging technologies and state-of-the-art processes.  

 

Please note: full product details will be shown on our training portal IPI Academy where you can find out more and book

Biosimilars

In-house & bespoke training

A two-day seminar providing an essential overview of biosmilars and how they differ from the original biological product.

Rated by attendees to the public programme

Typically presented by Andrew Willis (bio)

Typical duration: 2 days
Pricing from £800 per attendee
Delivery: collaborative classroom

More @ IPI Academy

Biotechnology for the Non-Biotechnologist

In-house & bespoke training

An ideal course for non-scientists and scientists who need to understand the basic theory, principles, techniques and potential of biotechnology.

Rated by attendees to the public programme

Typically presented by Robert Alvarez (bio)
and 6 more leading experts

Typical duration: 3 days
Pricing from £1,200 per attendee
Delivery: collaborative classroom

More @ IPI Academy

Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products

In-house & bespoke training

The regulatory requirements for Biological drug products are complex, and pharmaceutical companies are continuously under pressure to ensure regulatory compliance from drug discovery to post-marketing surveillance.
This course has been designed to help you navigate the complex regulatory requirements for biological drugs, including ATMPs. It will clearly depict the differences between small and large molecules and the development approaches which reflect the type of molecule. It will address the key aspects of the CTD, look at the CMC regulatory requirements during different stages of development, and discuss the importance of change control.

Rated by attendees to the public programme

Typically presented by Andrew Willis (bio)

Typical duration: 2 days
Delivery: collaborative classroom

More @ IPI Academy

Delivery of Biologics to the Nasal Cavity

In-house & bespoke training

The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. This is an ideal opportunity to hear from experts in the field of nasal drug delivery who will address topics such as: challenges associated with formulation, barriers to cell penetration and absorption, the pros and cons for liquid versus powder formulations, and strategies for maintaining stability and prolonging retention in the nasal cavity.

Rated by attendees to the public programme

Typically presented by Irene Rossi (bio)
and 3 more leading experts

Typical duration: 4 days
Delivery: collaborative classroom

More @ IPI Academy

US FDA - Understanding Key Factors When Working with the FDA

In-house & bespoke training

This course has been designed to provide an essential overview of the critical factors when working with the FDA (Food and Drug Administration).  For those short on time this course is for you, as you will receive a focused and comprehensive overview of the key strategic considerations when making applications to the FDA.  

Typically presented by Andrew Willis (bio)

Delivery: collaborative classroom

More @ IPI Academy

Very clear and informative!

Serge PAMPFER, CEO, Maedia

I thought all the speakers were excellent. You could tell that they all really knew there subject matter and were so passionate in the way they delivered the content. Special mention has to go to Adekunle - fantastic course leader and so knowledgeable and made the 3 days very interactive.

Mark Kalinowski, Chief Financial officer, Albumedix Ltd

The webinar had enough information for anyone to start their CMC biologics career or who is interested to do so. Or even for someone with biologics experience is looking to have additional knowledge and information can attend this training.
Andrew's knowledge and experience was proven very well.

Vineet Gavankar, Manager, Regulatory Affairs, PharmaLex UK Services Limited

The webinar was an excellent overview and insight into an emerging field - good balance of market intel and technical detail.

Eleanor Catherine Canipa, Senior Business Development Manager, Nanopharm (an Aptar Company)

The course was good and it was a pleasure to learn from the speakers. I wanted to get an overview of research and development of drugs and pharmaceuticals. I think this was achieved.

Sarah Kanna, Senior Legal Associate, Hevolution Foundation

It felt comprehensive.
An excellent resource going forward.

James McCracken, Quality Audit Manager , Advanz Pharma

Webinar was good, informative and lots of information. Speakers are well knowledgeable about Biosimilar Industry.

Srikanth Varma Kc, Global Audit and Due Diligence QA Manager, Abbott

The content was thorough. The presentation was informative. The speaker was very knowledgeable, helpful and friendly.

Sheena Singadia, Scientist II, Arecor

Very good

Jurgen Vercruysse, Business Unit Manager Drug Product, Eurofins Amatsigroup

The speaker was very good, the slides were clear and the explanations exhaustive.

Chiara Giaconi, Global Regulatory Affairs Oncology CMC Manager, Menarini Ricerche S.p.A.